anticancer/hnačka

Odkaz sa uloží do schránky

Vyberte typ zoradenia

Strana 1 od 2224 výsledky

Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Combining anticancer drugs with different mechanisms of action has the potential to enhance antitumor effect. CPT-11 (Camptosar, irinotecan), a topoisomerase I inhibitor, has been shown to be highly effective in the treatment of a variety of cancers. However, its clinical usage is often complicated

Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE An antitumor camptothecin derivative CPT-11 has proven a broad spectrum of solid tumor malignancy, but its severe diarrhea has often limited its more widespread use. We have demonstrated from a rat model that intestinal beta-glucuronidase may play a key role in the development of

Management of cancer treatment-related diarrhea. Issues and therapeutic strategies.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The cancer treatment-related diarrhea caused by acute graft-versus-host disease (GVHD) and chemotherapeutic agents, particularly fluoropyrimidines and irinotecan, significantly affects patient morbidity and mortality. The mechanisms causing cancer treatment-related diarrhea are not fully understood,

The assessment and management of cancer treatment-related diarrhea.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Cancer treatment-induced diarrhea affects a high percentage of patients with cancer that receive chemotherapy or radiation treatment. Widely used criteria for measuring treatment-induced diarrhea, such as the National Cancer Institute Common Toxicity Criteria, do not account for important

[Diarrhea caused by systemic anti-cancer treatments].

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Diarrhea is one of the most common complaints in oncologic patients. Causes are multiple including bowel resection, infections, radiation and systemic anti-cancer treatments. In the latter case, the pathophysiology is partially elucidated and requires the etiology to be precisely identified :

Cancer treatment-induced diarrhea: interventions to minimize the roller coaster ride.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

This program used a case-study approach to discuss interventions that nurses can implement in their daily clinical environment to minimize cancer treatment-induced diarrhea. Manifestations of cancer treatment-induced diarrhea, medical treatment options, and nutritional interventions were covered.

Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group phase III double-blind placebo-controlled trial.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE Randomized studies have suggested that sucralfate is effective in mitigating diarrhea during pelvic radiation therapy (RT). This North Central Cancer Treatment Group study was undertaken to confirm the antidiarrheal effect of sucralfate. Several other measures of bowel function were also

Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Irinotecan (CPT-11), a first-line chemotherapy for advanced colorectal cancer, causes serious diarrhea in patients receiving treatment. The underlying mechanism has been shown that the active metabolite of CPT-11, SN-38, is metabolized to the inactive metabolite SN-38 glucuronide (SN-38 G) during

Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To evaluate and compare the influence of dietary elements on cancer progression, chemotherapy efficacy, and toxicity, particularly severe, late-onset diarrhea related to irinotecan (CPT-11) treatment. METHODS We used laboratory rats fed a standardized basal diet, Ward colon tumor, and

Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea. METHODS An expert multidisciplinary panel was convened to review the recent literature and discuss recommendations for updating the practice guidelines

Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE The effectiveness and improvement in quality of life (QOL) of a long-acting formulation of octreotide (LAR) administration for cancer patients, with chronic loperamide-refractory diarrhea not attributed to medical therapy, were investigated. METHODS Twenty-nine patients with chronic

Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To assess the effectiveness of depot octreotide for the prevention of diarrhea during pelvic radiation therapy. METHODS Patients receiving pelvic radiation therapy (planned minimum dose, 45 Gy; 1.7 to 2.1 Gy daily) were eligible for the study. From May 10, 2002, through October 14, 2005,

[Management of cancer treatment-related diarrhea and constipation].

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Digestive complications are frequent dose-limiting side-effect of chemotherapy. Diarrhea and constipation can affect quality of life and alter optimum treatment efficacy. The incidence and the severity of these toxicities have to be systematically evaluated in order to provide specific curative and

New strategies for the prevention and reduction of cancer treatment-induced diarrhea.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To describe possible new strategies for the prevention of CTID. METHODS Abstracts presented at oncology meetings, primary and secondary literature, trial protocols, and clinical experience. CONCLUSIONS Patients who have experienced an episode of diarrhea are at high risk for developing

Management of acute cancer treatment-induced diarrhea.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To describe the dietary and pharmacologic management of acute CTID. METHODS Primary and secondary literature, and clinical experience. CONCLUSIONS When dietary strategies do not work, or when patients present with grade 3/4 diarrhea, pharmacologic intervention is required. First-line

Predchádzajúce
1
2
3
4
5
6
...
148
149
Ďalšie

Pripojte sa k našej
facebookovej stránke

Herbal & Natural Medicine

Najkompletnejšia databáza liečivých bylín podporovaná vedou

Pracuje v 55 jazykoch
Bylinné lieky podporené vedou
Rozpoznávanie bylín podľa obrázka
Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
Vyhľadajte liečivé byliny podľa ich účinkov
Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi

Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume